Oryzon develops Epigenetic Therapies against Cancer and Alzheimer’s

22/07/2016 - 2 minutes

This week we’re exchanging a very warm and welcoming country for another. We are heading to Barcelona, the wonderful capital of Catalunya in Spain, to visit Oryzon, our Biotech of The Week and maybe (just maybe) have a little swim in the Barceloneta beach.

oryzon logo biotech week

City: Barcelona (Spain)

Founded: 2000

Employees: 35

Financial Data: €81.50M Market Cap (Bolsa de Madrid)

Related Content

CEO: Carlos Buesa

carlos buesa ceo oryzon biotech week

Mission: Oryzon is a clinical-stage biopharma and a European leader in epigenetics-based therapeutics. In the beginning of its operations (2000-2008), Oryzon focused on genomics diagnostics. In 2008, it acquired Crystax Pharmaceuticals and started its own drug discovery programs.

Building on its platforms in genomics and epigenomics, Oryzon is able to identify biomarkers that can be translated into new therapeutic targets. Specifically, it focused on the development of small molecules for oncology and neurodegenerative diseases.

Its candidates target lysine-specific demethylase 1 (LSD1/KDM1A),

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT Do you want to remove this advert? Become a member!
ADVERTISEMENT Do you want to remove this advert? Become a member!

You might also be interested in the following:


Support Us

Become a Member